<DOC>
	<DOCNO>NCT01967940</DOCNO>
	<brief_summary>Part 1 consist 2 cohort , start sentinel cohort , 10 participant enrol receive open-label tenofovir alafenamide ( TAF ) addition current fail antiretroviral ( ARV ) regimen . This cohort follow randomize , double-blind , cohort compare addition TAF placebo-to-match TAF HIV-1 positive adult fail current ARV regimen . This randomized cohort consist approximately 90 participant . In Part 2 , participant complete Part 1 study discontinue fail ARV regimen TAF placebo-to-match TAF 14-day washout period . Following washout period , participant receive TAF Part 1 &gt; 0.5 log10 decline HIV-1 RNA receive elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide single-tablet regimen ( E/C/F/TAF STR ) plus atazanavir ( ATV ) daily 48 week . Participants receive TAF ≤ 0.5 log10 decline HIV-1 RNA discontinue study eligible continue Part 2 study . All participant receive placebo Part 1 eligible participate Part 2 regardless viral load change .</brief_summary>
	<brief_title>Efficacy Tenofovir Alafenamide Versus Placebo Added Failing Regimen Followed Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir HIV-1 Positive , Antiretroviral Treatment-Experienced Adults</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Cobicistat</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<criteria>Key Ability understand sign write informed consent form , must obtain prior initiation study procedure Currently take fail ARV regimen Screening historical genotype report show either 1 3 thymidineanalogue mutation ( TAMs ) and/or K65R , well M184V/I Plasma HIV1 RNA ≥ 500 copies/mL ≤ 100,000 copies/mL screen Normal ECG Estimated glomerular filtration rate ( eGFR ) ≥ 50 mL/min accord CockcroftGault formula creatinine clearance Alanine aminotransferase ( AST ) /aspartate aminotransferase ( AST ) ≤ 5 × upper limit normal range ( ULN ) Total bilirubin ≤ 1.5 mg/dL , normal direct bilirubin Adequate hematologic function Serum amylase ≤ 5 × ULN Females may enter study confirm : Not pregnant nursing Of nonchildbearing potential ( ie , hysterectomy , ovary remove , medically document ovarian failure , postmenopausal woman &gt; 54 year age cessation [ ≥ 12 month ] previously occur menses ) , Of childbearing potential agrees utilize highly effective contraception method nonheterosexually active practice sexual abstinence screen throughout duration study treatment 30 day follow study drug dose Females utilize hormonal contraceptive one birth control method must use method least three month prior study dose . Males must agree utilize highly effective method contraception heterosexual intercourse nonheterosexually active , practice sexual abstinence first dose throughout study period 30 day follow last study drug dose . Males must agree refrain sperm donation first dose least 30 day last study drug dose . Key A new AIDSdefining condition diagnose within 30 day prior screen Hepatitis B surface antigen ( HBsAg ) positive Hepatitis C antibody positive ( Subjects positive HCV antibody without detectable HCV RNA permit enroll ) History integrase inhibitor use Screening historical genotype report show Q151M T69ins 3 TAMs . Screening historical genotype report show resistance integrase inhibitor Individuals experience decompensated cirrhosis Current alcohol substance use History malignancy within past 5 year ( prior screen ) ongoing malignancy cutaneous Kaposi 's sarcoma ( KS ) , basal cell carcinoma , resect , noninvasive cutaneous squamous carcinoma . Individuals cutaneous KS eligible , must receive systemic therapy KS within 30 day Part 1 , Day 1 must anticipate require systemic therapy study . Active , serious infection ( HIV1 infection ) require parenteral antibiotic antifungal therapy within 30 day prior Part 1 , Day 1 Any clinical condition prior therapy would make individual unsuitable study unable comply dose requirement Participation clinical trial ( include observational trial ) without prior approval sponsor prohibit participate trial Receiving ongoing therapy disallow medication , include drug use elvitegravir , cobicistat , emtricitabine tenofovir alafenamide know allergy excipients E/C/F/TAF STR Note : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>HIV</keyword>
	<keyword>Treatment-Experienced</keyword>
</DOC>